Zioxtenzo

Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round
Endpoints
Sun, 01/29/17 - 11:53 am
Novartis
biosimilars
Zioxtenzo
Europe
Amgen
Neulasta
China